Based on previous findings [6,9–12], these observations suggest that GDF15 expression in NAFLD [14] occurs in a compensatory manner and that targeting this pathway may ameliorate obesity and related disorders. Here, GDF15 is linked to metabolic dysfunction-associated steatotic liver disease.